Bevacizumab is an anti-angiogenic compound, and more specifically, a monoclonal immunoglobulin that targets vascular endothelial growth factor (VEGF), that has been widely used for the treatment of retinal diseases. Here, VEGFA is linked to Abnormal retinal morphology.